Batu Publishes Oncotarget Paper

Batu Biologics Publishes Mechanistic Preclinical Data for ValloVax

Company authors peer reviewed publication describing the mechanism of action of the ValloVax™ mediated immune response

Batu Biologics, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today the publication of mechanistic data for the ValloVax platform in the current issue of Oncotarget.

Read the full article at businesswire.com

Continue →
0

Batu announces formation of Clinical Advisory Board

Batu Biologics Welcomes Three Visionary Leaders to Its Newly Formed Clinical Advisory Board

CAB to oversee the clinical development of Batu Biologics’ tumor vasculature targeting immunotherapeutic, ValloVax™

Batu Biologics, a San Diego based immuno-oncology company focused on the development of its tumor angiogenesis targeting immune therapy, ValloVax™, announced today the formation of a Clinical Advisory Board to guide the company in the development of its lead program.

Read the full article at businesswire.com

Continue →
0

Batu Recruits Internationally Recognized Immunologist

Internationally-Recognized Immunologist Joins Batu Biologics’ Quest to Destroy Solid Tumors

Francesco Marincola, MD, Joins Batu’s Scientific Advisory Board

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor endothelium vaccine, ValloVax™, announced today the appointment of Francesco M. Marincola, MD, FACS, to its scientific advisory board.

Read the full article at businesswire.com

Continue →
0

Batu Seeks New Approach to Inhibit Immune Checkpoints

Batu Biologics Utilizes CRISPR/cas9 Gene Editing to Modify T Cells

Immune Checkpoint Silenced T Cells for More Potent, Longer Lasting Anti-Tumor Responses

Batu Biologics, an immuno-oncology company, has recently filed intellectual property and initiated discovery research on a new method of augmenting an anti-tumor immune response through ex vivo manipulation of the patient’s T cells.

Read the full article at businesswire.com

Continue →
0

ValloVax Efficacy Augmented by Checkpoint Inhibitors

Batu Biologics Reports Combination Therapy Boosts Results in Tumor Blood Vessel-Killing Strategy

Company Files Patent on Second Generation Cancer Therapy

Batu Biologics, an immuno-oncology company dedicated to the commercialization of its first-in-class tumor blood vessel targeting vaccine, ValloVax, reported today filing of a patent application covering a unique combination therapy of its vaccine together with two classes of “checkpoint inhibitors.”

Read the full article at businesswire.com

Continue →
0

Batu Biologics files IP for immune modulator

Batu Biologics Files Patent on Blood Derived Anti-Cancer Immunomodulator

Cancer Angiogenesis Vaccine Company Expands its Therapeutic Pipeline

Batu Biologics announced today filing of a patent application covering a recent finding by the company regarding ability to stimulate innate immune system through products that are coaxed out of white blood cells by stimulation with non-toxic agents.

Read the full article at businesswire.com

Continue →
0

Batu Biologics Appoints Dr. Santosh Kesari to SAB

Batu Biologics Appoints Dr. Santosh Kesari to Scientific Advisory Board

UC San Diego Moores Cancer Expert to evaluate the clinical potential of ValloVax for Glioblastoma

Batu Biologics, an immuno-oncology company based out of San Diego dedicated to the development of its polyvalent tumor endothelium vaccine, ValloVax, announced today the appointment of Santosh Kesari, MD, PhD, FANA to its scientific advisory board.

Read the full article at businesswire.com

Continue →
0
Page 1 of 4 1234